peptides
Fat Blaster 10mg
Fat Blaster is a compounded lipolytic research blend pairing methionine/inositol/choline-class cofactors with L-carnitine. Studied for hepatic lipid handling, fatty-acid transport, and body-composition endpoints in preclinical models.
Research-observed benefits
- ›Fatty-acid mobilization
- ›Hepatic lipid support
- ›Metabolic cofactor delivery
- ›Body-composition endpoints
Findings reported in in-vitro / preclinical research literature. Not therapeutic claims.
CAS Number
—
Purity
99%+
Molecular Formula
—
Stock
120 units
Order type
Purchase option
Quantity
Total
$80
For in-vitro research only. Not for human consumption, diagnostic, or therapeutic use. Storage at -20°C recommended for lyophilized peptides.
Fat Blaster 10mg — Full Research Breakdown
Tailored information for researchers. All content is for in-vitro / preclinical research context only — not medical advice.
Mechanism of Action
Lipotropic cofactor blend: methionine supports hepatic fat export via methyl donation, inositol and choline mobilize stored lipid from hepatocytes, and L-carnitine shuttles long-chain fatty acids into the mitochondria for beta-oxidation.
How It Helps
Supports the transport and oxidation half of fat metabolism rather than appetite suppression, making it a common comparator in body-composition and hepatic-lipid research.
Half-Life
Component-dependent; carnitine ~15 hours, choline/inositol pools turn over daily
Onset of Effects
Metabolic marker shifts typically evaluated at 4–8 weeks in study models.
Storage
Store 2–8°C protected from light; do not freeze solution presentations.
Stacks Well With
- ›AOD-9604 (lipolytic signaling)
- ›MOTS-c (mitochondrial output)
- ›Tesamorelin (visceral fat)
Research-Observed Side Effects
- •Injection-site stinging
- •Transient fishy odor (choline)
- •Mild GI upset in models
Translational Cautions
- •Hepatic or renal impairment models
- •Known sensitivity to B-complex components
Research Highlights
- ▸Carnitine supplementation improves fatty-acid oxidation capacity in controlled trials.
- ▸Choline deficiency reliably produces hepatic steatosis in animal models.
- ▸Inositol shown to improve insulin signaling markers in metabolic-syndrome cohorts.